CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Tislelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03209973
NCT03209973Phase 2Completed
CompareCT.gov

A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

BeiGene·interventional·Posted Jul 6, 2017·Updated Feb 5, 2025

In Brief

A Phase 2 clinical trial evaluating Tislelizumab for Classical Hodgkin Lymphoma. Completed, enrolled 70 participants across 12 sites.

Detailed Summary

The primary objective of this study was to evaluate the efficacy of tislelizumab assessed by Independent Review Committee (IRC) in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassical Hodgkin Lymphoma
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 6, 2017
Enrollment StartApr 21, 2017
Primary CompletionNov 2, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.0 years ago

Interventions

Tislelizumabdrug

Administered as specified in the treatment arm